Showing 2,121 - 2,140 results of 2,974 for search '"drug interaction"', query time: 0.34s Refine Results
  1. 2121

    Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability by Cookinham S, Collins CD, Smith J

    Published 2011-07-01
    “…Miconazole buccal tablets exhibit few drug interactions because of low systemic absorption and are generally well tolerated with a safety profile similar to comparators. …”
    Get full text
    Article
  2. 2122

    Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine by Linda Sangalli, Stefania Brazzoli

    Published 2023-01-01
    “…As they are migraine-specific therapies, they largely expand their use to patients that could not tolerate previous treatments, either for systemic contraindications or drug-to-drug interactions, or where any other available option was not efficacious. …”
    Get full text
    Article
  3. 2123

    Are improper kinetic models hampering drug development? by Ryan Walsh

    Published 2014-10-01
    “…The empirical approach to inhibition modeling presented here is broadly applicable allowing easy comparison and rational analysis of drug interactions. To demonstrate this, a simple kinetic model of DAPT, a compound that both activates and inhibits γ-secretase is examined using excel. …”
    Get full text
    Article
  4. 2124

    Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. by Wei Dou, Subhajit Mukherjee, Hao Li, Madhukumar Venkatesh, Hongwei Wang, Sandhya Kortagere, Ariel Peleg, Sridhar S Chilimuri, Zheng-Tao Wang, Ying Feng, Eric R Fearon, Sridhar Mani

    Published 2012-01-01
    “…Pharmacological targeting of intestinal PXR using natural metabolically labile ligands could serve as effective and potent therapeutics for gut inflammation that avert systemic drug interactions.…”
    Get full text
    Article
  5. 2125

    OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications. by Ruwen Böhm, Leocadie von Hehn, Thomas Herdegen, Hans-Joachim Klein, Oliver Bruhn, Holger Petri, Jan Höcker

    Published 2016-01-01
    “…OpenVigil FDA provides disproportionality analyses to (i) identify the drug most likely evoking a new adverse event, (ii) compare two drugs concerning their safety profile, (iii) check arbitrary combinations of two drugs for unknown drug-drug interactions and (iv) enhance the relevance of results by identifying confounding factors and eliminating them using background correction. …”
    Get full text
    Article
  6. 2126

    Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV by Sara Iannuzzi, Max von Kleist

    Published 2021-07-01
    “…However, it is unclear whether, and which, direct drug–drug interactions mediate the apparent synergy. The goal of this work was to refine a mechanistic model for the molecular mechanism of action (MMOA) of nucleoside analogues in order to analyse whether putative direct interactions may account for the in vitro observed synergistic effects. …”
    Get full text
    Article
  7. 2127

    Electrophysiological Characterization of Spontaneously Contracting Cell Aggregates Obtained from Rainbow Trout Larvae with Multielectrode Arrays by Julia M. Mehnert, Matthias Brandenburger, Bianka Grunow

    Published 2013-11-01
    “…Ranging from cell-based systems to model organisms, no model available to date reflects the complexity of the human heart and evokes the great need for improved and more affordable systems. Many drugs interact with hERG potassium channels and consequently cause life threatening ventricular arrhythmias, further highlighting the importance of suitable model systems. …”
    Get full text
    Article
  8. 2128

    Supplementary Pharmacotherapy for the Behavioral Abnormalities Caused by Stressors in Humans, Focused on Post-Traumatic Stress Disorder (PTSD) by Jeffrey Fessel

    Published 2023-02-01
    “…Using low doses of chosen drugs will limit both toxicity and drug-drug interactions. A clinical trial is required to validate both the advocated concept and the choice of drugs.…”
    Get full text
    Article
  9. 2129

    Safety issues regarding melatonin use in child and adolescent patients with sleep problems by Eunsoo Moon, Jung Hyun Lee

    Published 2022-12-01
    “…It is necessary to monitor potential drug interactions with medications such as inhibitors and enhancers of cytochrome P450 1A2 (CYP1A2). …”
    Get full text
    Article
  10. 2130

    Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management by Serena Barachini, Gabriele Buda, Iacopo Petrini

    Published 2024-03-01
    “…Understanding how these drugs interact with the heart and blood vessels is essential for predicting, detecting, and managing chemotherapy-related heart issues.…”
    Get full text
    Article
  11. 2131

    Physicians’ attitude towards community pharmacists’ contribution in the treatment decision making by Rebar Ali Mohammed, Bushra Hassan Marouf

    Published 2023-01-01
    “…Furthermore, the physicians’ perspective on the pharmacists’ role showed that advising patients on drug administration (85.1%) and preventing drug interactions (76.6%) were the most common duties of the community pharmacists. …”
    Get full text
    Article
  12. 2132

    Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing by Bridget Myers, Vidhatha Reddy, Stephanie Chan, Quinn Thibodeaux, Nicholas Brownstone, John Koo

    Published 2022-01-01
    “…Then, it explores internal and external reasons why doxepin plasma levels and clinical response vary so significantly between patients, including genetic polymorphisms, drug interactions, comorbidities, sex, and ethnicity. Blood level monitoring is introduced, a tool dermatologists can use to optimize doxepin dosing in patients responding subtherapeutically to typical dermatologic doses. …”
    Get full text
    Article
  13. 2133
  14. 2134

    COVID-19 and gastrointestinal disease: implications for the gastroenterologist by Hunt, RH, East, JE, Lanas, A, Malfertheiner, P, Satsangi, J, Scarpignato, C, Webb, GJ

    Published 2020
    “…The risk for drug-drug interactions is considerable in patients seriously ill with COVID-19 who often require mechanical ventilation and life support. …”
    Journal article
  15. 2135

    The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. by Champness, J, Achari, A, Ballantine, S, Bryant, P, Delves, C, Stammers, D

    Published 1994
    “…CONCLUSIONS: These structures show how two drugs interact with a fungal DHFR. A comparison of the three-dimensional structure of this relatively large DHFR with bacterial or mammalian enzyme-inhibitor complexes determined previously highlights some additional secondary structure elements in this particular enzyme species. …”
    Journal article
  16. 2136

    The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. by Champness, J, Achari, A, Ballantine, S, Bryant, P, Delves, C, Stammers, D

    Published 1994
    “…CONCLUSIONS: These structures show how two drugs interact with a fungal DHFR. A comparison of the three-dimensional structure of this relatively large DHFR with bacterial or mammalian enzyme-inhibitor complexes determined previously highlights some additional secondary structure elements in this particular enzyme species. …”
    Journal article
  17. 2137

    Cognitive-behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review by Koychev, I, Okai, D

    Published 2017
    “…Pharmacological treatment is the main approach in dealing with these symptoms, but it is limited by variable efficacy and risk of drug interactions. Non-pharmacological approaches using the cognitive-behavioural therapy (CBT) model are viable alternatives and in this review paper we summarise the evidence of CBT for three of the most common psychiatric manifestations of PD: depression and anxiety, impulse-control disorders and insomnia. …”
    Journal article
  18. 2138

    Evaluation Of Tacrolimus, Associated Adverse Effects, Quality Of Life, And Treatment Satisfaction Among Kidney Transplant Patients In Riyadh, Saudi Arabia by Ahmed Alboghdadly, Amany Mohamed Hussien

    Published 2023
    “…Due to tacrolimus- unwanted adverse effects, narrow therapeutic index, drug-drug interactions, and significant inter-individual variability in pharmacokinetics, it requires constant therapeutic drug monitoring. …”
    Get full text
    Thesis
  19. 2139
  20. 2140

    Ionic Polymethacrylate Based Delivery Systems: Effect of Carrier Topology and Drug Loading by Dorota Neugebauer, Anna Mielańczyk, Rafał Bielas, Justyna Odrobińska, Maria Kupczak, Katarzyna Niesyto

    Published 2019-07-01
    “…The studies indicated that the well-defined ionic polymethacrylates, including poly(ionic liquid)s, are advantageous for designing macromolecular carriers due to the variety of structural parameters, which are efficient for tuning of drug loading and release behavior in respect to the specific drug interactions.…”
    Get full text
    Article